These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 23107590)

  • 1. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
    Kornmann M; Staib L; Wiegel T; Kron M; Henne-Bruns D; Link KH; Formentini A;
    Clin Colorectal Cancer; 2013 Mar; 12(1):54-61. PubMed ID: 23107590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stratified Survival Analysis After Adjuvant Chemotherapy of Colon Cancer Reveals a Benefit for Older Patients.
    Mayer B; Sander S; Paschke S; Henne-Bruns D; Link KH; Kornmann M;
    Anticancer Res; 2015 Oct; 35(10):5587-93. PubMed ID: 26408730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) with folinic acid (FA) in adjuvant therapy of colon cancer.
    Wein A; Riedel C; Brückl W; Kastl S; Reingruber B; Hohenberger W; Hahn EG
    Z Gastroenterol; 2001 Feb; 39(2):153-6. PubMed ID: 11253506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
    Jpn J Clin Oncol; 1995 Jun; 25(3):91-103. PubMed ID: 7596054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
    André T; Quinaux E; Louvet C; Colin P; Gamelin E; Bouche O; Achille E; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Lledo G; Raoul Y; Debrix I; Buyse M; de Gramont A
    J Clin Oncol; 2007 Aug; 25(24):3732-8. PubMed ID: 17704423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.
    Taal BG; Van Tinteren H; Zoetmulder FA;
    Br J Cancer; 2001 Nov; 85(10):1437-43. PubMed ID: 11720425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
    Schippinger W; Samonigg H; Schaberl-Moser R; Greil R; Thödtmann R; Tschmelitsch J; Jagoditsch M; Steger GG; Jakesz R; Herbst F; Hofbauer F; Rabl H; Wohlmuth P; Gnant M; Thaler J;
    Br J Cancer; 2007 Oct; 97(8):1021-7. PubMed ID: 17895886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α.
    Kornmann M; Staib L; Wiegel T; Kreuser ED; Kron M; Baumann W; Henne-Bruns D; Link KH
    Br J Cancer; 2010 Oct; 103(8):1163-72. PubMed ID: 20877353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
    Kornmann M; Formentini A; Ette C; Henne-Bruns D; Kron M; Sander S; Baumann W; Kreuser ED; Staib L; Link KH
    Eur J Surg Oncol; 2008 Dec; 34(12):1316-21. PubMed ID: 18313881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
    Fountzilas G; Zisiadis A; Dafni U; Konstantaras C; Hatzitheoharis G; Papavramidis S; Bousoulegas A; Basdanis G; Giannoulis E; Dokmetzioglou J; Katsohis C; Nenopoulou E; Karvounis N; Briassoulis E; Aravantinos G; Kosmidis P; Skarlos D; Pavlidis N
    Oncology; 2000 Apr; 58(3):227-36. PubMed ID: 10765125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy with or without pelvic radiotherapy after simultaneous surgical resection of rectal cancer with liver metastases: analysis of prognosis and patterns of recurrence.
    An HJ; Yu CS; Yun SC; Kang BW; Hong YS; Lee JL; Ryu MH; Chang HM; Park JH; Kim JH; Kang YK; Kim JC; Kim TW
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):73-80. PubMed ID: 22300562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
    Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
    Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report.
    Cafiero F; Gipponi M; Lionetto R;
    J Surg Oncol; 2003 Jul; 83(3):140-6. PubMed ID: 12827681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
    Hong KD; Lee SI; Moon HY
    Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.
    Schippinger W; Jagoditsch M; Sorré C; Gnant M; Steger G; Hausmaninger H; Mlineritsch B; Schaberl-Moser R; Mischinger HJ; Hofbauer F; Holzberger P; Mittlböck M; Jakesz R;
    Br J Cancer; 2005 May; 92(9):1655-62. PubMed ID: 15856042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.
    Köhne CH; Bedenne L; Carrato A; Bouché O; Popov I; Gaspà L; Valladares M; Rougier P; Gog C; Reichardt P; Wils J; Pignatti F; Biertz F
    Eur J Cancer; 2013 May; 49(8):1868-75. PubMed ID: 23571150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
    Poplin EA; Benedetti JK; Estes NC; Haller DG; Mayer RJ; Goldberg RM; Weiss GR; Rivkin SE; Macdonald JS
    J Clin Oncol; 2005 Mar; 23(9):1819-25. PubMed ID: 15774775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.